Healthcare Bio-Pharma Field Rep Survey Findings

Data and insights from participants across oncology, neurology, immune system diseases, cardiovascular and pain management

Significant market dynamics are greatly impacting bio-pharma reps.

75% of clinical trials are occurring outside of “big pharma”
50% of new products are orphan drugs
Biosimilars are now a more acceptable alternative due to product price increases

With these adverse market conditions, high performing bio-pharma companies are providing additional support to sales reps:

54% are more likely to have a managed care team
Pay levels are 6% higher than low performing peers
Reps are leveraging digital capabilities
Firms are providing a strong omnichannel presence

What additional attributes should bio-pharma companies be considering to help sales reps adapt to evolving market headwinds and customer needs?

For a full, complimentary briefing on Alexander Group’s Bio-Pharma Field Rep Survey findings, please complete the form and a healthcare practice leader will be in contact with you.